A Bayesian dose-finding design for drug combination clinical trials based on the logistic model

Pharmaceutical Statistics

Volumn 13, Issue 4, 2014, Pages 247-257

  Riviere, Marie Karelle ^a,b   Yuan, Ying ^c   Dubois, Frédéric ^b   Zohar, Sarah ^a  

^a INSERM   (France)

^b IRIS Institut de Recherches Internationales Servier   (France)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Bayesian inference; dose finding; drug combination; oncology; phase I trial

Indexed keywords

AREA UNDER THE CURVE; ARTICLE; BAYES THEOREM; CALIBRATION; CLINICAL TRIAL (TOPIC); DOSE CALCULATION; DRUG COMBINATION; DRUG TOXICITY; LOGISTIC REGRESSION ANALYSIS; MATHEMATICAL ANALYSIS; MATHEMATICAL MODEL; MAXIMUM PERMISSIBLE DOSE; MAXIMUM TOLERATED DOSE; PHASE 2 CLINICAL TRIAL (TOPIC); SENSITIVITY ANALYSIS; SIMULATION; STATISTICAL ANALYSIS; STATISTICAL MODEL; COMBINATION DRUG THERAPY; COMPUTER SIMULATION; HUMAN; PROCEDURES;

BAYES THEOREM; CLINICAL TRIALS AS TOPIC; COMPUTER SIMULATION; DRUG DOSAGE CALCULATIONS; DRUG THERAPY, COMBINATION; HUMANS; LOGISTIC MODELS;

EID: 84904469426     PISSN: 15391604     EISSN: 15391612     Source Type: Journal    
DOI: 10.1002/pst.1621     Document Type: Article

References (31)

1. Zhou Y,. Choice of designs and doses for early phase trials. Fundamental & Clinical Pharmacology 2004; 18 (3): 373-378.
2. Chevret S,. Statistical methods for dose-finding experiments, Statistics in Practice. John Wiley and Sons Ltd.: Chichester, 2006.
3. Common terminology criteria for adverse events (CTCAE) and common toxicity criteria (CTC), National Cancer Institute. Rockville, Maryland, USA, 2009.
4. Conaway MR, Dunbar S, Peddada SD,. Designs for single- or multiple-agent phase I trials. Biometrics 2004; 60: 661-669.
5. Wages NA, Conaway MR, O'Quigley J,. Continual reassessment method for partial ordering. Biometrics 2011; 67 (4): 1555-1563.
6. Thall PF, Millikan RE, Mueller P, Lee SJ,. Dose-finding with two agents in phase I oncology trials. Biometrics 2003; 59 (3): 487-496.
7. Wang K, Ivanova A,. Two-dimensional dose finding in discrete dose space. Biometrics 2005; 61: 217-222.
8. Mandrekar SJ, Cui Y, Sargent DJ,. An adaptive phase I design for identifying a biologically optimal dose for dual agent drug combinations. Statistics in Medicine 2007; 26: 2317-2330.
9. Mandrekar SJ, Qin R, Sargent DJ,. Model-based phase I designs incorporating toxicity and efficacy for single and dual agent drug combinations: methods and challenges. Statistics in Medicine 2010; 29: 1077-1083.
10. Yin G, Yuan Y,. A latent contingency table approach to dose finding for combinations of two agents. Biometrics 2009; 65: 866-875.
11. Yin G, Yuan Y,. Bayesian dose finding in oncology for drug combinations by copula regression. Journal of the Royal Statistical Society: Series C (Applied Statistics) 2009; 58: 211-224.
12. Bailey S, Neuenschwander B, Laird G, Branson M,. A Bayesian case study in oncology phase I combination dose-finding using logistic regression with covariates. Journal of Biopharmaceutical Statistics 2009; 19: 469-484.
13. Riviere MK, Dubois F, Zohar S,. Competing designs for drug combination in phase I dose-finding clinical trials. Statistics in Medicine 2014. DOI: 10.1002/sim.6094.
14. Faries D,. Practical modifications of the continual reassessment method for phase I cancer clinical trials. Journal of Biopharmaceutical Statistics 1994; 4: 147-64.
15. Goodman SN, Zahurak ML, Piantadosi S,. Some practical improvements in the continual reassessment method for phase I studies. Statistics in Medicine 1995; 14 (11): 1149-1161.
16. Korn EL, Midthune D, Chen TT, Rubinstein LV, Christian MC, Simon RM,. A comparison of two phase I trial designs. Statistics in Medicine 1994; 13: 1799-806.
17. O'Quigley J, Zohar S,. Experimental designs for phase I and phase I/II dose-finding studies. British Journal of Cancer 2006; 94 (5): 609-613.
18. Iasonos A, Wilton AS, Riedel ER, Seshan VE, Spriggs DR,. A comprehensive comparison of the continual reassessment method to the standard 3+3 dose escalation scheme in phase I dose-finding studies. Clinical Trials 2008; 5 (5): 465-477.
19. Yuan Y, Yin G,. Sequential continual reassessment method for two-dimensional dose finding. Statistics in Medicine 2008; 27 (27): 5664-5678.
20. Ivanova A, Wang K,. A non-parametric approach to the design and analysis of two-dimensional dose-finding trials. Statistics in Medicine 2004; 23: 1861-1870.
21. O'Quigley J, Pepe M, Fisher L,. Continual reassessment method: a practical design for phase 1 clinical trials in cancer. Biometrics 1990; 46: 33-48.
22. Zohar S, Resche-Rigon M, Chevret S,. Using the continual reassessment method to estimate the minimum effective dose in phase II dose-finding studies: a case study. Clinical Trials 2013; 10 (3): 414-421.
23. Gilks WR, Best NG, Tan KKC,. Adaptive rejection metropolis sampling within Gibbs sampling. Journal of the Royal Statistical Society: Series C (Applied Statistics) 1995; 44: 455-472.
24. Sweeting MJ, Mander AP,. Escalation strategies for combination therapy phase I trials. Pharmaceutical Statistics 2012; 11 (3): 258-266.
25. Thall PF, Simon R,. Practical Bayesian guidelines for phase IIB clinical trials. Biometrics 1994; 50 (2): 337-349.
26. Storer BE,. Design and analysis of phase I clinical trials. Biometrics 1989; 45: 925-37.
27. Ivanova A, Montazer-Haghighi A, Mohanty SG, Durham SD,. Improved up-and-down designs for phase I trials. Statistics in Medicine 2003; 22 (1): 69-82.
28. Simon R, Freidlin B, Rubinstein L, Arbuck SG, Collins J, Christian MC,. Accelerated titration designs for phase I clinical trials in oncology. Journal of the National Cancer Institute 1997; 89 (15): 1138-1147.
29. Gasparini M, Bailey S, Neuenschwander B,. Bayesian dose finding in oncology for drug combinations by copula regression. Journal of the Royal Statistical Society: Series C (Applied Statistics) 2010; 59: 543-546.
30. Cheung YK, Chappell R,. Sequential designs for phase I clinical trials with late-onset toxicities. Biometrics 2000; 56 (4): 1177-1182.
31. Cheung YK, Thall PF,. Monitoring the rates of composite events with censored data in phase II clinical trials. Biometrics 2002 Mar; 58 (1): 89-97.